BTIG analyst Mark Massaro lowered the firm’s price target on NeoGenomics (NEO) to $18 from $21 and keeps a Buy rating on the shares. The stock ...

BTIG keeps a Buy rating on Mersana Therapeutics (MRSN) with a $6 price target after the company presented data for Emi-Le from the Phase I ...

Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Palo Alto Networks (NASDAQ: PANW) investors just cannot catch a break. Over the past three days, this cybersecurity stock has been downgraded by three separate investment bank analysts, beginning with ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...